Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:administeredBy |
gptkb:tablet
|
| gptkbp:alsoKnownAs |
gptkb:infigratinib
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:United_States
cholangiocarcinoma with FGFR2 fusion or rearrangement |
| gptkbp:ATCCode |
L01EX20
|
| gptkbp:CASNumber |
872511-34-7
|
| gptkbp:clinicalTrialPhase |
Phase 2
|
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:hasInChIKey |
gptkb:QJQYQKZDHGQXQJ-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C26H31N7O3
|
| gptkbp:hasSMILES |
CC1=CC(=C(N=C1)N2CCN(CC2)C3=NC4=C(N3)C=CC(=C4)C5=CC=CC=C5)C(=O)N
|
| https://www.w3.org/2000/01/rdf-schema#label |
BGJ398
|
| gptkbp:indication |
cholangiocarcinoma
|
| gptkbp:mechanismOfAction |
FGFR inhibitor
|
| gptkbp:molecularWeight |
489.57 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
fatigue
alopecia dysgeusia hyperphosphatemia nail toxicity stomatitis dry eye |
| gptkbp:target |
gptkb:FGFR3
gptkb:FGFR1 gptkb:FGFR4 gptkb:FGFR2 |
| gptkbp:usedIn |
clinical trials
|
| gptkbp:bfsParent |
gptkb:CD332
|
| gptkbp:bfsLayer |
7
|